Filtering by:
Cancer in AdolescentsAdolescent and Young Adult Cancer Survival Rates Increase When Re-evaluated
A new way of looking at the data of adolescents and young adults (AYAs) with cancer shows survival rates among this age group are much better than previously thought.
When Adolescents and Young Adults Get Cancer
When an adolescent or young adult gets cancer, treatment can be challenging. At an age characterized by the beginnings of independence, the increased reliance on parents that accompanies a cancer diagnosis often complicates care.
Facts & Figures 2018: Rate of Deaths From Cancer Continues Decline
The death rate from cancer in the US has declined steadily over the past 2 decades, according to annual statistics reporting from the American Cancer Society.
Could Infections Teach Us How to Make Treatments for Pediatric ALL Even Better?
Alix Seif, MD, MPH, is studying a new type of immunotherapy that could teach the immune system long-term memory. The goal is for the immune system to kill any new leukemia cells for the rest of the child's life.
The Current and Future Promise of Immunotherapy for Childhood Cancers
Immunotherapy offers hope to children with cancer who don't respond to standard treatments. The new drug, Kymriah, is likely only the first to use CAR T-cell therapy, which helps immune cells identify cancer cells and kill them.
FDA Approves CAR T-cell Therapy for Pediatric Acute Lymphoblastic Leukemia (ALL)
The US Food and Drug Administration (FDA) has approved Kymriah (tisagenlecleucel) for certain children, adolescents, and young adults with a form of acute lymphoblastic leukemia (ALL).
Young Thyroid Cancer Survivor Pursues Education Goals
Michelle Rodriguez, 20, is determined nothing will stop her from her lifelong goal of being the first one in her family to get a college degree – not even a diagnosis of thyroid cancer.
Panel Backs CAR T-cell Therapy for Leukemia: What You Need to Know and What’s Next
The US and Drug Administration (FDA) this week convened a panel of outside experts to weigh in on the readiness of a first-of-its-kind cancer treatment called CAR T-cell therapy. The panel unanimously recommended that the agency approve the treatment. What does this mean for patients? And is CAR T-cell therapy going to play an increasing role in cancer treatment in general? In this interview, Leonard Lichtenfeld, MD, MACP, American Cancer Society deputy chief medical officer, gives us his take.
